Response to statin therapy in the real world

被引：2
作者：
Attar, Armin [1 ]
机构：
[1] Shiraz Univ Med Sci, TAHA Clin Trial Grp, Dept Cardiovasc Med, Shiraz, Iran
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 14期
关键词：
ATORVASTATIN;
D O I：
10.1177/2047487320905718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E25 / E26
页数：2
相关论文
共 12 条
  • [1] Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada
    Alter, David A.
    Tu, Jack V.
    Koh, Maria
    Jackevicius, Cynthia A.
    Austin, Peter C.
    Rezai, Mohammad R.
    Bhatia, R. Sacha
    Johnston, Sharon
    Udell, Jacob A.
    Ko, Dennis T.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (10):
  • [2] The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe
    Bielecka-Dabrowa A.
    Aronow W.S.
    Rysz J.
    Banach M.
    [J]. Current Cardiovascular Risk Reports, 2011, 5 (2) : 174 - 179
  • [3] Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study
    De Bacquer, Dirk
    De Smedt, Delphine
    Reiner, Zeljko
    Tokgozoglu, Lale
    Clays, Els
    Kotseva, Kornelia
    Ryden, Lars
    Wood, David
    De Backer, Guy
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (15) : 1630 - 1636
  • [4] Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER
    Karlson, Bjorn W.
    Wiklund, Olov
    Palmer, Michael K.
    Nicholls, Stephen J.
    Lundman, Pia
    Barter, Philip J.
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2016, 2 (04) : 212 - 217
  • [5] Gauging the treatment gap in dyslipidemia: Findings from the 1999-2000 National Health and Nutrition Examination Survey
    Klingman, D
    Williams, SA
    Benner, JS
    Smith, TW
    Ahn, J
    O'Donnell, JC
    [J]. AMERICAN HEART JOURNAL, 2005, 150 (03) : 595 - 601
  • [6] Lin Iris, 2016, J Manag Care Spec Pharm, V22, P685, DOI 10.18553/jmcp.2016.22.6.685
  • [7] Mach F, 2018, EUR HEART J, V39, P2526, DOI 10.1093/eurheartj/ehy182
  • [8] Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US
    Marrett, Elizabeth
    Zhao, Changgeng
    Zhang, Ning Jackie
    Zhang, Qiaoyi
    Ramey, Dena R.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    Neff, David R.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 237 - 246
  • [9] Masson M, 2014, REV ARGENT CARDIOL, V82, P34, DOI [10.7775/rac.es.v82.i1.2882, DOI 10.7775/RAC.ES.V82.I1.2882]
  • [10] Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner
    Pedro-Botet, J
    Schaefer, EJ
    Bakker-Arkema, RG
    Black, DM
    Stein, EM
    Corella, D
    Ordovas, JM
    [J]. ATHEROSCLEROSIS, 2001, 158 (01) : 183 - 193
12